Paradigm Biopharmaceuticals' Phase 3 osteoarthritis program is granted Fast Track Designation by FDA

Name: Paradigm Biopharmaceuticals' Phase 3 osteoarthritis program is granted Fast Track Designation by FDA
Uploaded: 2022-04-12T16:47:00Z
Description: Paradigm Biopharmaceuticals' Phase 3 osteoarthritis program is granted Fast Track Designation by FDA

Proactive Published 12/04/2022

Share X in f @

Paradigm Biopharmaceuticals Ltd (ASX:PAR) Chief Medical Officer and Interim CEO Dr. Donna Skerrett tells Proactive the Melbourne, Australia-based clinical stage biopharmaceutical company has been granted Fast Track Designation for the company’s phase 3 program to treat osteoarthritis.

Dr. Skerett says this will provide opportunity for shorter review timelines for the group, which is focused on repurposing existing drugs for new indications.